The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials
Bjorner JB, Larsen S, Lübker C, Holst-Hansen T
Diabetes Obes Metab. 2023;25(8):2142-2150.
Leggi
Effect of multifactorial intensive treatment in patients with diabetic kidney disease: A meta‐analysis with trial sequential analysis
Shan J, Xu Z
Diabetes Obes Metab. 2023;25(8):2163-2170.
Leggi
Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial
Svanevik M, Lorentzen J, Borgeraas H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00127-4.
Leggi
Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study
Larose S, Filliter C, Platt RW, et al.
Diabetes Obes Metab. 2023;25(8):2279-2289.
Leggi
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
Kang A, Smyth B, Neuen BL, et al.
Diabetes Obes Metab. 2023;25(8):2151-2162.
Leggi
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Aroda VR, Aberle J, Bardtrum L, et al.
The Lancet 2023. Pub. online 25 June 2023.
Leggi
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Liane Ong K, Stafford LK, McLaughlin SA, et al.
Lancet. 2023;S0140-6736(23)01301-6.
Leggi
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias JP, Deenadayalan S, Erichsen L, et al.
The Lancet 2023. Pub. online 23 June 2023.
Leggi
Assessment of atherothrombotic risk in patients with type 2 diabetes mellitus
Berg DD, Moura FA, Bellavia A, et al.
J Am Coll Cardiol. 2023,81(25):2391-2402.
Leggi